Keeping You Updated
InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct® After Phase IIa Trial Achieves Clinical Endpoints Early
Oxford, UK- 18th May 2009 - PharmaVentures Ltd, announced today that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures' transactions experience in the healthcare and investment business sectors.
Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials.
Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program.
Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors.”
InDex will be presenting Phase II data at BIO on Wednesday 20th May. See also InDex’s Press Release released today: http://www.indexpharmab.com/images/pdf/kappaproctmay2009.pdf
Visit PharmaVentures during BIO at booths 4209 & 4211 for further information on this and other licensing opportunities.
For enquiries about this opportunity, please contact:
Dr Adrian Dawkes
Managing Consultant
PharmaVentures
adrian.dawkes@pharmaventures.com
+44 (0) 1865 784 193
- ends -
Notes to Editors:
PharmaVentures® (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clientsâ growth ambitions in the health care industry. It comprises two divisions: PharmaVentures Corporate Advisory and PharmaVentures Business Media which produces the highly popular PharmaDeals® range of intelligence products including analysis tools and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (http://www.pharmatelevision.com). PharmaTelevision News is a daily âmust seeâ news service broadcast worldwide.
Now in its 12th year, PharmaVentures is based in Oxford, UK, employs over 30 people, many educated to PhD level. It is active worldwide, including the USA and AsiaPacific. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisors, investment companies and governments.
For further information please contact:
Lisa Holloway
Marketing
lisa.holloway@pharmaventures.com